Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Cima Labs Inc. (NasdaqNM:CIMA)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Location
10000 Valley View Road
Eden Praire, MN 55344
Phone: (952) 947-8700
Fax: (952) 947-8770
Email: ep1@cimalabs.com
Employees (last reported count): 140
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 42%
·Over the last 6 months:
 · 9 insider sells; 157.0K shares
  (2.5% of insider shares)
·Institutional: 95% (164% of float)
(204 institutions)
·Net Inst. Buying: 378.0K shares (+2.63%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Cima Labs Inc. develops and manufactures pharmaceutical products based on its proprietary OraSolv and DuraSolv fast-dissolve technologies. The Company manufactures five pharmaceutical brands utilizing its DuraSolv and OraSolv technologies. They consist of three prescription and two over-the-counter brands. These products include Triaminic Softchews for Novartis; Tempra FirsTabs for a Canadian affiliate of Bristol-Myers Squibb; Zomig-ZMT and its equivalent for the European market, Zomig Rapimelt, for AstraZeneca; Remeron SolTab for Organon, and NuLev for Schwarz Pharma. In addition to OraSolv and DuraSolv, the Company is developing transmucosal oral drug delivery technologies. These technologies include OraVescent SL for drug delivery under the tongue, OraVescent BL for drug delivery between the gum and the cheek and OraVescent SS for swallowable site-specific drug delivery in the gastrointestinal tract.
More from Market Guide: Expanded Business Description

Financial Summary
Cima Labs Inc. is a drug delivery company that develops and manufactures products based upon its patented OraSolv technology for marketing by multinational pharmaceuticals companies. For the six months ended 6/30/01, revenues rose 22% to $14 million. Net income before accounting change totaled $6.7 million, up from $942 thousand. Results reflect an increase in shipments of branded prescription products, improved margins, and higher interest income.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Terrence Glarner, 57
Chairman
--  --  
John Siebert, Ph.D., 61
Pres and CEO
$454K$2.4M
John Hontz, Ph.D., 44
COO
291K2.2M
David Feste, 49
VP, CFO, Sec.
173K640K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:CIMAAs of 31-Aug-2001
Price and Volume
52-Week Low
on 18-Sep-2000
$33.50 
Recent Price$53.53 
52-Week High
on 7-June-2001
$85.75 
Beta0.27 
Daily Volume (3-month avg)362.7K
Daily Volume (10-day avg)276.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change+27.8%
52-Week Change
relative to S&P500
+71.5%
Share-Related Items
Market Capitalization$787.6M
Shares Outstanding14.7M
Float8.50M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$13.65 
Earnings (ttm)$0.70 
Earnings (mrq)$0.22 
Sales (ttm)$1.83 
Cash (mrq)$3.72 
Valuation Ratios
Price/Book (mrq)3.92 
Price/Earnings (ttm)76.25 
Price/Sales (ttm)29.23 
Income Statements
Sales (ttm)$26.5M
EBITDA (ttm)$6.16M
Income available to common (ttm)$10.5M
Profitability
Profit Margin (ttm)39.7%
Operating Margin (ttm)15.2%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)7.92%
Return on Equity (ttm)8.15%
Financial Strength
Current Ratio (mrq)16.04 
Debt/Equity (mrq)0 
Total Cash (mrq)$54.7M
Short Interest
As of 8-Aug-2001
Shares Short1.03M
Percent of Float12.1%
Shares Short
(Prior Month)
1.26M
Short Ratio2.36 
Daily Volume437.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.